Clinical Trial Update: In Vivo Characterization of Inflammation With Ferumoxytol, an Ultrasmall Superparamagnetic Iron Oxide Nanoparticle, on 7 Tesla Magnetic Resonance Imaging [Phase 1]

View source ↗

Summary

Phase 1 clinical trial update evaluating ferumoxytol-enhanced 7 Tesla MRI to characterize inflammation in multiple sclerosis; the study status is completed.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Multiple Sclerosis

Drugs mentioned

• FERUMOXYTOL (ferumoxytol)

Snippet

Sponsor: National Institute of Neurological Disorders and Stroke (NINDS) | Conditions: Multiple Sclerosis | Phase 1 | Status: COMPLETED